secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2026-10-06T11:51:50+00:00
Accession:  0001104659-26-113895
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 2.02, 8.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Regeneron, Sanofi expand antibody collaboration; Sanofi to pay $1B upfront, up to $7B in milestones
--------------------------------------------------------------------------------

- Sixth Amendment to 2009 Antibody LCA covers four new Regeneron antibodies: IL-13, IL-4, IL-4Rα, and IL-4xIL-13 bispecific.
- Sanofi to make $1.0B upfront payment; Regeneron eligible for up to $7.0B in development, regulatory, commercial milestones; global profits split 50/50.
- Regeneron gets option, per asset after ongoing trials, to add Sanofi's Phase 2/3 lunsekimig (TSLPxIL-13 Nanobody) and another early asset; would reimburse certain dev costs.
- Regeneron lead development and pre-approval regulatory party; lead US regulatory/commercialization; Sanofi leads commercialization and ex-US regulatory.
- Q3 2026 to include ~$22M pre-tax acquired IPR&D charge, cutting GAAP and non-GAAP EPS by ~$0.18; results not final. Dupixent audit lawsuit dismissed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000110465926113895/0001104659-26-113895-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000110465926113895/tm2627077d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-113895

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer